{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:56:15Z","timestamp":1785455775550,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1007\/bf02982806","type":"journal-article","created":{"date-parts":[[2008,11,5]],"date-time":"2008-11-05T12:13:48Z","timestamp":1225887228000},"page":"411-419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan"],"prefix":"10.1007","volume":"76","author":[{"given":"Kensei","family":"Tobinai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,12,1]]},"reference":[{"issue":"suppl 5","key":"BF02982806_CR1","first-page":"75","volume":"20","author":"SJ Horning","year":"1993","unstructured":"Horning SJ. Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas.Semin Oncol. 1993; 20(suppl 5): 75\u201388.","journal-title":"Semin Oncol."},{"key":"BF02982806_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1200\/JCO.1997.15.2.445","volume":"15","author":"PJ Bierman","year":"1997","unstructured":"Bierman PJ, Vose JM, Anderson JR, et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin\u2019s lymphoma.J Clin Oncol. 1997; 15: 445\u2013450.","journal-title":"J Clin Oncol."},{"key":"BF02982806_CR3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.Blood. 1994; 83: 435\u2013445.","journal-title":"Blood"},{"key":"BF02982806_CR4","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.Blood. 1994; 84: 2457\u20132466.","journal-title":"Blood"},{"key":"BF02982806_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.Nat Med. 2000; 6: 443\u2013446.","journal-title":"Nat Med."},{"key":"BF02982806_CR6","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","volume":"15","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8 results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma.J Clin Oncol. 1997; 15: 3266\u20133274.","journal-title":"J Clin Oncol."},{"key":"BF02982806_CR7","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rit-uximab) anti-CD20 antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma.Blood. 1997; 90: 2188\u20132195.","journal-title":"Blood"},{"key":"BF02982806_CR8","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998; 16: 2825\u20132833.","journal-title":"J Clin Oncol."},{"key":"BF02982806_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1023\/A:1008265313133","volume":"9","author":"K Tobinai","year":"1998","unstructured":"Tobinai K, Kobayashi Y, Narabayashi M et al. Feasibility and phar-macokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma.Ann Oncol. 1998; 9: 527\u2013534.","journal-title":"Ann Oncol."},{"key":"BF02982806_CR10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/annonc\/mdf155","volume":"13","author":"T Igarashi","year":"2002","unstructured":"Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.Ann Oncol. 2002; 13: 928\u2013943.","journal-title":"Ann Oncol."},{"issue":"(suppl 1)","key":"BF02982806_CR11","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1007\/s002800100313","volume":"48","author":"K Tobinai","year":"2001","unstructured":"Tobinai K. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin\u2019s lymphoma in Japan.Cancer Chemother Phamacol. 2001; 48(suppl 1): S85-S90.","journal-title":"Cancer Chemother Phamacol."},{"key":"BF02982806_CR12","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.Blood. 1994; 84: 1361\u20131392.","journal-title":"Blood"},{"key":"BF02982806_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF02981940","volume":"73","author":"T Igarashi","year":"2001","unstructured":"Igarashi T, Ohtsu T, Fujii H, et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab.Int J Hematol. 2001; 73: 213\u2013221.","journal-title":"Int J Hematol."},{"key":"BF02982806_CR14","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.Blood. 1998; 92: 1927\u20131932.","journal-title":"Blood"},{"key":"BF02982806_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","volume":"18","author":"JM Foran","year":"2000","unstructured":"Foran JM, Rohatiner AZS, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.J Clin Oncol. 2000; 18: 317\u2013324.","journal-title":"J Clin Oncol."},{"key":"BF02982806_CR16","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment.J Clin Oncol. 2000; 18: 3135\u20133143.","journal-title":"J Clin Oncol."},{"key":"BF02982806_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1046\/j.1365-2141.1999.01608.x","volume":"106","author":"K Schmitz","year":"1999","unstructured":"Schmitz K, Brugger W,Weiss B, Kaiserling E, Kanz L. Clonal selection of CD20-negative non-Hodgkin\u2019s lymphoma cells after treatment with anti-CD20 antibody rituximab [letter].Br J Haematol. 1999; 106: 571\u2013572.","journal-title":"Br J Haematol."},{"key":"BF02982806_CR18","first-page":"611","volume":"5","author":"TA Davis","year":"1999","unstructured":"Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.Clin Cancer Res. 1999; 5: 611\u2013615.","journal-title":"Clin Cancer Res."},{"key":"BF02982806_CR19","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood.V93.7.2427","volume":"93","author":"INM Micallef","year":"1999","unstructured":"Micallef INM, Kirk A, Norton A, Foran JM, Rohatiner AZS, Lister TA. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma [letter].Blood. 1999; 93: 2427\u20132428.","journal-title":"Blood"},{"key":"BF02982806_CR20","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1200\/JCO.1998.16.12.3916","volume":"16","author":"T Kinoshita","year":"1998","unstructured":"Kinoshita T, Nagai H, Murate T, Saito H. CD20-negative relapse in B-cell lymphoma after treatment with rituximab [letter].J Clin Oncol. 1998; 16: 3916.","journal-title":"J Clin Oncol."},{"key":"BF02982806_CR21","first-page":"286a","volume":"21","author":"T Igarashi","year":"2002","unstructured":"Igarashi T, Itoh K, Kobayashi Y, et al. Phase II and pharmacokinetic study of rituximab with eight weekly infusions in relapsed aggressive B-cell non-Hodgkin\u2019s lymphoma (B-NHL).Proc Am Soc Clin Oncol. 2002; 21: 286a.","journal-title":"Proc Am Soc Clin Oncol."},{"key":"BF02982806_CR22","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lym-phomas.J Clin Oncol. 1999; 17: 1244\u20131253.","journal-title":"J Clin Oncol."},{"key":"BF02982806_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","volume":"17","author":"MS Czuczman","year":"1999","unstructured":"Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.J Clin Oncol. 1999; 17: 268\u2013276.","journal-title":"J Clin Oncol."},{"key":"BF02982806_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","volume":"19","author":"JM Vose","year":"2001","unstructured":"Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin\u2019s lymphoma.J Clin Oncol. 2001; 19: 389\u2013397.","journal-title":"J Clin Oncol."},{"key":"BF02982806_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rit- uximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med. 2002; 346: 235\u2013242.","journal-title":"N Engl J Med."},{"key":"BF02982806_CR26","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","volume":"17","author":"TE Witzig","year":"1999","unstructured":"Witzig TE, White CA,Wiseman GA, et al. Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin\u2019s lymphoma.J Clin Oncol. 1999; 17: 3793\u20133803.","journal-title":"J Clin Oncol."},{"key":"BF02982806_CR27","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioim-munotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma.J Clin Oncol. 2002; 20: 2453\u20132463.","journal-title":"J Clin Oncol."},{"key":"BF02982806_CR28","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","volume":"19","author":"MS Kaminski","year":"2001","unstructured":"Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas.J Clin Oncol. 2001; 19: 3918\u20133928.","journal-title":"J Clin Oncol."},{"key":"BF02982806_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJM200107263450402","volume":"345","author":"RJ Kreitman","year":"2001","unstructured":"Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy cell leukemia.N Engl J Med. 2001; 345: 241\u2013247.","journal-title":"N Engl J Med."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF02982806\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02982806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02982806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02982806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T23:45:13Z","timestamp":1659051913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF02982806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["BF02982806"],"URL":"https:\/\/doi.org\/10.1007\/bf02982806","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12]]},"assertion":[{"value":"8 July 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}